Australian-Singaporean regenerative medicine company Osteopore (ASX: OSX) is delighted to present its results for Q2 CY23.
HIGHLIGHTS
- Achieving record quarterly revenues of A$587,226 in Q2 CY23, a 43% increase on Q1 CY23.
- Signing a A$10m non-binding term sheet with CellHeal Therapeutics to propel commercialisation in China.
- Promoting Dr Lin Jing to the role of CEO and appointing Hon. Michael Keenan as Non-Executive Director.
- Raising A$908,660 in its oversubscribed shortfall placement.
- Signing a A$4m binding term sheet with CellHeal Therapeutics to pursue commercialisation in China.
- Signing non-binding term sheets with Accelerate Technologies to pursue the commercialisation of bioactive compounds.
- Signing an exclusive distribution partnership with Majeton to distribute products in Singapore.
- Securing reimbursement approval from DHMS – South Africa’s biggest medical insurer – for Osteomesh®.
- Transitioning to the new European Union Medical Device Regulation 2017/745 (MDR).
- Securing a sub-distribution partnership with Kelyniam to boost its presence on the US East Coast.
